May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Bevacizumab Injection in Von Hippel Lindau Disease
Author Affiliations & Notes
  • O. Ustariz–Gonzalez
    Retina, APEC, Mexico, Mexico
  • A. Suarez–Lincona
    Retina, APEC, Mexico, Mexico
  • H. Quiroz–Mercado
    Retina, APEC, Mexico, Mexico
  • J. Guerrero–Naranjo
    Retina, APEC, Mexico, Mexico
  • A. Perez–Reguera
    Retina, APEC, Mexico, Mexico
  • D. Moreno–Paramo
    Retina, APEC, Mexico, Mexico
  • G. Alvarez–Rivera
    Retina, APEC, Mexico, Mexico
  • A. Amaya–Espinosa
    Retina, APEC, Mexico, Mexico
  • F. Furno–Sola
    Retina, APEC, Mexico, Mexico
  • Footnotes
    Commercial Relationships  O. Ustariz–Gonzalez, None; A. Suarez–Lincona, None; H. Quiroz–Mercado, None; J. Guerrero–Naranjo, None; A. Perez–Reguera, None; D. Moreno–Paramo, None; G. Alvarez–Rivera, None; A. Amaya–Espinosa, None; F. Furno–Sola, None.
  • Footnotes
    Support  Rioarronte Foundation
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 4713. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      O. Ustariz–Gonzalez, A. Suarez–Lincona, H. Quiroz–Mercado, J. Guerrero–Naranjo, A. Perez–Reguera, D. Moreno–Paramo, G. Alvarez–Rivera, A. Amaya–Espinosa, F. Furno–Sola; Bevacizumab Injection in Von Hippel Lindau Disease . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4713.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To report safety and efficacy of intravitreal Bevacizumab (Avastin, Genetec. Inc) in two patients with Von Hippel Lindau Disease.

Methods: : Two eyes of 2 patients were treated with intravitreal Bevacizumab. Complete ophthalmic evaluation, visual acuity and fluorescein angiography (FA) were evaluated before and after 3 months of follow–up.

Results: : Both patients increase their visual acuity. One patient from –1.40 to –1.00 LogMAR and the other from –1.40 to –0.80 LogMAR. Vitreous opacity by ophthalmoscopy and color photos decreased in both eyes and FA showed less leakage.

Conclusions: : Intravitreal Bevacizumab was a safe treatment and decreased vascular permeability at 3 months follow–up.

Keywords: retina • tumors • retinal neovascularization 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.